Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Capital Expenditures (2018 - 2025)

Neurogene (NGNE) has disclosed Capital Expenditures for 4 consecutive years, with $927000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures rose 420.79% year-over-year to $927000.0, compared with a TTM value of $1.1 million through Sep 2025, up 53.34%, and an annual FY2024 reading of $726000.0, changed N/A over the prior year.
  • Capital Expenditures was $927000.0 for Q3 2025 at Neurogene, up from -$652000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $927000.0 in Q3 2025 and bottomed at -$652000.0 in Q2 2025.